Phase 2 Medical Manufacturing Completes Corporate Re-Branding Initiative

Phase 2 Medical Manufacturing Completes Corporate Re-Branding Initiative

Phase 2 Medical Manufacturing, Inc. has completed an intensive re-branding initiative in conjunction with Harbour Light Strategic Marketing. The process included a brand audit, new corporate logo, new website, trade show booths and sales collateral materials. - March 11, 2011 - Phase 2 Medical Manufacturing, Inc.

Carmel Pharma Sponsors National Safe Handling Awareness Month -- Returns in April

National Safe Handling Awareness Month Returns in April 2011 Annual campaign increases education about/awareness of hazardous drug exposure National Safe Handling Awareness Month – a campaign to further education surrounding the safe handling of hazardous drugs in the healthcare setting... - February 27, 2011 - Carmel Pharma

SHL to speak at Drug Delivery System Development and Lifecycle Management Requirements for Biologic Pharmaceuticals: Trends and Best Practices

Lucio Giambattista, Executive Vice President of the SHL Group & Managing Director of SHL Medical, USA to speak at the DCAT Week 11 Conference, Biologics Forum & Networking Reception March 16th 2011 in New York City. - February 24, 2011 - SHL Group (Scandinavian Health Group Ltd)

SHL Expands Range of Automation Solutions for Auto Injector Assembly

Using the latest technology and software available, SHL Automation has developed a sub-assembly equipment that is robust, efficient and addresses various common bottlenecks of automated systems. - February 12, 2011 - SHL Group (Scandinavian Health Group Ltd)

GenScript Corporation Has Installed the First BiacoreTM T200 Biosensor in the World

GenScript Corporation and GE Healthcare Life Sciences China together held an opening ceremony on Dec 22nd 2010 in Nanjing China, to celebrate the successful installation of the first unit of BiacoreTM T200 instrument in the world. To an audience of primarily research scientists from both big... - January 19, 2011 - GenScript USA Inc.

BPA in Medical Devices - is This a Concern? Carmel Pharma's PhaSeal Closed-System Drug Transfer Device (CSTD) Does Not Contain BPA.

Bisphenol A (BPA) is a substance used to make common polycarbonate plastic. However, the growing global concern regarding the health effects of this substance has lead several countries and organizations to issue health warnings. BPA will be banned in the manufacture of baby bottles 2011 in the... - January 14, 2011 - Carmel Pharma

GenScript Received OLAW (Office of Laboratory Animal Welfare) Approval for Animal Welfare Assurance

GenScript received the approval of Animal Welfare Assurance for its animal facility on 9 Nov, 2010. This approval accentuates the responsibilities and procedures of GenScript regarding the care and use of laboratory animals. - November 24, 2010 - GenScript USA Inc.

Immunologix Teams with GenScript to Produce Human Antibody Therapeutics Ready for Clinical Trials

Immunologix, Inc, a Charleston, SC biotechnology company and a leader in fully human therapeutic antibodies for a variety of diseases and GenScript, a contract research organization (CRO) based in Piscataway, NJ and the industry leader in bio-reagent services, assay development & screening,... - November 11, 2010 - GenScript USA Inc.

GenScript Launches CloneReadyTM Gene Collections

GenScript’s CloneReadyTM Gene Collections provide convenient and cost-effective solutions to researchers’ gene related practices. - September 09, 2010 - GenScript USA Inc.

InnoCore and Nanomi Strengthen Collaboration in Microsphere Technology for Peptide and Protein Delivery

InnoCore Technologies BV and Nanomi BV announce a strategic collaboration for the development of advanced monodisperse biodegradable microsphere-based controlled release formulations for the sustained delivery of biotherapeutics. - July 14, 2010 - Nanomi

Electronic Cigarette Review Website Sees Huge Increase in Visitors with New Smoking Bans in Place

The review team at Electronic Cigarettes Reviews.net has witnessed a huge increase in reviews written by consumers living in a state where a public smoking ban has been enacted in the past few months. Many consumers are sharing thoughts and opinions on electronic cigarettes and offering advice for other consumers to make informed decisions on whether to purchase a certain brand of e-cigarettes. - July 07, 2010 - ElectronicCigarettesReviews.net

Buchberger Laboratories Austria Unveiling WOYZEK® Nicotine Inhaler

For the first time Buchberger Laboratories Austria is releasing detailed information on its most promising pharmaceutical product candidate – the WOYZEK® Nicotine Inhaler – a cigarette smoking cessation aid for medium and long-term use. - June 04, 2010 - Buchberger Laboratories Austria

Electronic Cigarettes Reviews Website Launches Awards Section for the Best E-Cigarette Brands in Various Categories

ElectronicCigarettesReviews.net, a website that provides consumers with reviews for many major brands of electronic cigarettes, launched a new section for awards in various categories. The awards section comes after the success and positive feedback from many of the reader reviews of electronic cigarette brands. Visit the awards section to see which electronic cigarette brands came out the winners. - May 20, 2010 - ElectronicCigarettesReviews.net

Carmel Pharma/PhaSeal® Exhibiting at Booth #1923 at ONS Congress

Booth Attractions Include Product Demonstrations, “Passport to Care” and More. - May 05, 2010 - Carmel Pharma

GenScript Launches Guaranteed Gene-to-Protein Service Package Following the Technology Breakthrough from OptimumGene™ Gene Optimization

Benefiting from its patent-pending OptimumGene™ gene optimization technology breakthrough which can achieve a 10-fold or greater increase in protein expression, GenScript now offers a first-to-market guaranteed Gene-to-Protein custom service package. - April 28, 2010 - GenScript USA Inc.

Archived Safe Handling Awareness Day CE Webinar Supported by Carmel Pharma Now Available

More than 1300 Participants Viewed Live Webinar Presentation on April 20. - April 26, 2010 - Carmel Pharma

Now Live: The “Safe Handling Dance” Video to Benefit the ASHP Foundation

Get Steppin’ to Safety -- 100,000 Views Equals a Charitable Donation to Further the Safe Handling of Hazardous Drugs. - April 09, 2010 - Carmel Pharma

Electronic Cigarette Review Website Adds a Section Specifically for E-Cigarette Cartridge and Cartomizer Reviews

ElectronicCigarettesReviews.net, a leading website for the assessment of electronic cigarettes, recently added a section to the website to review cartridges and cartomizers used in e-cigarettes. Now consumers can not only read reviews and make informed decisions on an overall brand of electronic cigarettes, but can also make an informed decision on buying e-cigarette cartridges and cartomizers. - April 09, 2010 - ElectronicCigarettesReviews.net

Electronic Cigarettes Reviews.net Unveils New Review Section for E-Cigarette Affiliate Programs

The electronic cigarette review website, ElectronicCigarettesReviews.net, recently added a review section for the various e-cigarette affiliate programs that are helping many online advertisers and marketers make a great living. Read the reviews on the various e-cigarette affiliate programs that are reviewed on the website and decide if marketing e-cigarettes could be a way to earn extra income. - March 24, 2010 - ElectronicCigarettesReviews.net

Complimentary CE Webinar Offered for Second Annual National Safe Handling Awareness Day (April 20, 2010)

Healthcare professionals are invited to participate in a free, one-hour safe handling CE webinar addressing the proper handling of hazardous drugs on April 20, 2010 – the Second Annual National Safe Handling Awareness Day. - March 02, 2010 - Carmel Pharma

Carmel Pharma to Sponsor the Return of National Safe Handling Awareness Month in April 2010

Annual campaign increases education about/awareness of hazardous drug exposure through complimentary CE programs and safe handling initiatives. - February 04, 2010 - Carmel Pharma

GenScript Recognized as Preferred Contract Supplier of Life Science Products by University of Pennsylvania

GenScript draws attention from UPENN School of Medicine for obtaining best quality products and services. - January 28, 2010 - GenScript USA Inc.

GenScript’s Presence in Japan Relocated from Osaka to Tokyo

GenScript plans to expand its Japanese market from its capital. - January 21, 2010 - GenScript USA Inc.

GenScript Launches Click Peptide Services

GenScript’s click peptide service aims to handle difficult peptide you intended to study. - January 21, 2010 - GenScript USA Inc.

New Year, New User-Inspired Products from Carmel Pharma

Smartly-designed components are even easier to use, offer reliable PhaSeal® protection. - January 20, 2010 - Carmel Pharma

Carmel Pharma/PhaSeal Exhibiting at Booth #2818 at ASHP MCM

Offerings Include Personalized Cost Savings Demonstrations, Blue Man Group Ticket Giveaways and More - November 22, 2009 - Carmel Pharma

Carmel Pharma Introduces PhaSeal® Secondary Set (C60)

New Component Streamlines Safe Spiking, Priming and IV Bag Infusion with Hazardous Drugs - November 01, 2009 - Carmel Pharma

Electronic Cigarette Users Now Have Forum to Review E-Cigarette Brands

Electronic cigarettes have been gaining much attention in the press. On http://www.electroniccigarettesreviews.net, readers receive the most accurate information on trends in this industry, as well as user reviews of various e-cigarette brands. - October 23, 2009 - ElectronicCigarettesReviews.net

Carmel Pharma/PhaSeal Exhibiting at Booth #720 at ONS IOL

Offerings to include Live pH Test demonstrations, Wii giveaway and more. - October 15, 2009 - Carmel Pharma

GenScript Established Biology Research Collaboration with Roche

GenScript expands its drug discovery services to assay development. - September 12, 2009 - GenScript USA Inc.

GenScript Launches Antibody Sequencing Service Geared Toward Innovation

GenScript’s antibody sequencing service aims to accelerate antibody drug discovery and patent applications. - September 05, 2009 - GenScript USA Inc.

GenScript Launches 20% Off Campaign Celebrating the 5th Anniversary of Peptide Service

GenScript celebrates its 5th anniversary for its peptide services by giving customers 20% off for standard peptide synthesis and modifications. - August 23, 2009 - GenScript USA Inc.

GenScript Expands Its THE™ Elite Antibody Series

GenScript adds THE™ Anti-DYKDDDDK mAb to the THE™ antibody series. - August 18, 2009 - GenScript USA Inc.

GenScript Upgrades Plasmid Production Platform to Deliver Potent Plasmids

GenScript upgrades its plasmid production platform to enable wider scope downstream applications. - August 07, 2009 - GenScript USA Inc.

GenScript Raises $15M for Drug Discovery and Development Services Expansion —Kleiner Perkins Invests in Biology CRO Business

GenScript Inc. received $15M investment led by Kleiner Perkins Caufield & Byers (KPCB) to expand its biology and bio-reagent services in drug discovery and development. - June 26, 2009 - GenScript USA Inc.

Nanomi Joins Consortium to Address Chronic Kidney Disease

Nanomi, a leading provider of microsphere-based drug delivery technologies to the pharmaceutical industry, announced today that it joined a consortium for the development of a therapy to prevent chronic kidney disease. In an aging population, the worldwide incidence of chronic kidney disease,... - June 25, 2009 - Nanomi

Genscript Offers Free Bio-Reagent Sample Bundles

GenScript offers high quality bundled bio-reagent samples to appreciate customers and assist in biology research under current tough economic condition. - May 10, 2009 - GenScript USA Inc.

GenScript Seeks Long-Term Collaboration Opportunities by Offering Special Partnership Promotion for Gene Synthesis

Internationally recognized biology contract research organization GenScript Corporation announces its special partnership promotion for gene synthesis service, which aims to establish a long-term, high-volume, and preferred vendor contract with its partners by offering them specially discounted... - April 22, 2009 - GenScript USA Inc.

Carmel Pharma/PhaSeal Exhibiting at Booth #251 at ONS Congress

Offerings Include Interactive Product Efficacy Demos, Opportunities to Speak with PhaSeal Developers, Complimentary Starbucks Cards and More. - April 17, 2009 - Carmel Pharma

April 2009 Declared National Safe Handling Awareness Month

National Campaign Aims to Protect Healthcare Workers from Hazardous Drug Exposure. - February 26, 2009 - Carmel Pharma

Free CE Webinar Offered for First-Ever National Safe Handling Awareness Day (April 20, 2009)

Healthcare professionals are invited to participate in a free, one-hour safe handling CE webinar addressing the proper handling of hazardous drugs on April 20, 2009, the inaugural Safe Handling Awareness Day. - February 24, 2009 - Carmel Pharma

Carmel Pharma/PhaSeal Exhibiting at Booth #1127 at ASHP MCM

Offerings Include Live Leakproof Integrity Test w/ Industry Thought Leaders, New Product Demos, Nintendo Wii Raffle and More. - December 05, 2008 - Carmel Pharma

Physicians Total Care Helps North Carolina Practice Integrate Physician Dispensing

Due to decreased reimbursements from managed care companies, Hickory Family Practice in Hickory, N.C., began looking for different avenues to increase profitability. Integrating physician medication dispensing through Physicians Total Care allowed Hickory Family Practice to generate additional revenue for the practice. - May 27, 2008 - Physicians Total Care

Carmel Pharma Introduces the Next Evolution of PhaSeal

Carmel Pharma, Inc. will introduce the new Injector N35 with ErgoMotion™ at the 33rd ONS Annual Congress in Philadelphia, PA. This new component employs the innovative and unique technology of ErgoMotion™ - a simple turn-key motion that provides easy access during hazardous drug... - May 16, 2008 - Carmel Pharma

Avanti Therapeutics Launches Chikujee Therapeutics, a Targeted Drug Delivery Company

Avanti Therapeutics, a privately held biopharmaceutical company, said it has incubated and launched a new bionanotechnology company for targeted drug delivery called Chikujee Therapeutics. Chikujee Therapeutics hopes to commercialize nanomedicines using its proprietary, cell specific targeted drug... - March 28, 2008 - Chikujee Therapeutics

Samaritan Pharmaceuticals Welcomes Two New Independent Directors to Its Board

Samaritan has appointed two new independent members, Jack L. Ayala and Robert W. Crane, to its Board of Directors. Mr. Ayala and Mr. Crane bring valuable experience and their appointment strengthens Samaritan's commitment to maintain a majority of independent members that reflects today's best practices on its Board. Samaritan's board is now comprised of eight independent directors and two internal directors. - January 09, 2008 - Samaritan Pharmaceuticals

Three Rivers Adds Territory of Ireland to Samaritan's Existing Exclusive Licensing Agreement to Market Amphocil in Greece and Cyprus

Samaritan has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals, LLC for fungal infection drug Amphocil to add the territory of Ireland. Currently, Samaritan has the marketing rights for Amphocil in Greece and Cyprus and has successfully registered and obtained a price increase for Amphocil in Greece. - January 09, 2008 - Samaritan Pharmaceuticals

Samaritan Announces the Granting of European Patent for New Type of Cardiovascular Plaque Clearing Drug SP-1000

Samaritan Pharmaceuticals has received a notice that a European Patent has been granted to Samaritan's SP-1000 (Cholesterol Recognition Sequence) drug for the treatment of cardiovascular disease. - January 09, 2008 - Samaritan Pharmaceuticals

Samaritan Pharma Strategically Advances Its Promising Alzheimer's Drug

Enters Service Agreement with Advinus Therapeutics, India to Validate Potential Memory Restoring Benefits of Alzheimer's Drug Caprospinol. Strategy is to Bolster Caprospinol Alzheimer's Data Package to Out-License to Big Pharma and Expand IND Application to Enter Human Trials. Samaritan... - January 09, 2008 - Samaritan Pharmaceuticals

FDA Accepts Samaritan's Cushing's SP-6300 IND and Clears Phase II Study

The U.S. Food and Drug Administration (FDA) has completed its regulatory review of Samaritan's IND (Investigational New Drug) application for Cushing's syndrome SP-6300 and declared it has not identified any deficiencies in its IND filing. Accordingly, Samaritan can proceed with its proposed Phase II clinical study of Cushing's syndrome SP-6300's efficacy in patients experiencing Hypercortisolism. - January 04, 2008 - Samaritan Pharmaceuticals

Press Releases 151 - 200 of 220